HCWB (HCW Biologics) Moat Score: 2/10 (As of Jun. 27, 2026)


HCWB HCW Biologics Inc HCWB
39 GF Score
Price $1.04
GF Value $7.29
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is HCW Biologics Moat Score?

HCW Biologics HCWB -7.62% 39 Moat Score is 2 as of Jun. 27, 2026. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $7.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,404 Biotechnology companies, HCW Biologics ranks better than 58.12% on this metric.

HCW Biologics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

HCW Biologics has No Moat: HCW Biologics Inc lacks significant market leadership or customer loyalty. The company does not exhibit strong network effects, cost advantages, or regulatory barriers. Its intellectual property and innovation capabilities are not sufficient to establish a durable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes HCW Biologics might have No Moat - Very weak/transient advantages.

HCW Biologics  (NAS:HCWB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

HCW Biologics Moat Score Related Terms

HCWB vs MTVA, INTI, HOOK: Moat Score Comparison

For the Biotechnology subindustry, HCW Biologics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HCW Biologics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's Moat Score distribution charts can be found below:

* The bar in red indicates where HCW Biologics's Moat Score falls into.


HCWB
39GF Score
HCW Biologics Inc HCWB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
HCW Biologics (HCWB) has a Moat Score of 2 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, HCW Biologics ranks #588 out of 1404 companies in the Biotechnology industry, placing it in the top 41.9%.
Is HCW Biologics' Moat Score too high?
HCW Biologics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. HCW Biologics' value of 2 is 0% at this industry median. Based on the distribution chart, HCW Biologics ranks #588 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Moat Score compare to MTVA and INTI?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #588 out of 1404 companies for Moat Score. This puts HCW Biologics in the upper half of its industry. The industry median Moat Score is 2.00. HCW Biologics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $1.04 — trading 85.7% below its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Moat Score is 2 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HCW Biologics (HCWB) Overvalued in 2026?

Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued. The current stock price of $1.04 is trading 85.7% below its estimated GF Value™ of $7.29. GuruFocus considers HCW Biologics to be Possible Value Trap.

Key valuation signals for HCWB:

  • Moat Score: 2
  • GF Value™: $7.29 vs. price of $1.04 (85.7% below fair value)
  • GF Score™: 39/100 with 7 warning signs
  • Industry Position: 0% at the Biotechnology median (#588 of 1404)

No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HCW Biologics Business Description

Address 2929 N. Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score

Get the complete analysis for HCWB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.04
Price
$7.29
GF Value